Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339480 | 0.89 | HTR2A (0.56) | TAAR1PARP1HTR2AHTR2CNISCH | |
| SCHEMBL24101668 | 0.89 | HTR2A (0.56) | TAAR1PARP1HTR2AHTR2CNISCH | |
| SCHEMBL46213 | 0.87 | NISCH (0.57) | TAAR1PARP1HTR2AHTR2CNISCH | |
| Hydrochloric Acid SCHEMBL14892523 | 0.86 | NISCH (0.55) | TAAR1PARP1HTR2AHTR2CNISCH | |
| SCHEMBL38664556 | 0.79 | TAAR1 (0.49) | TAAR1PARP1HTR2AHTR2CRAD52 | |
| SCHEMBL6299491 | 0.78 | PARP1 (0.50) | PARP1KDM4EAURKACCNB2CDK1 | |
| SCHEMBL31447884 | 0.77 | PARP1 (0.49) | PARP1KDM4EAURKACCNB2CDK1 | |
| SCHEMBL2247129 | 0.74 | AURKA (0.40) | PARP1AURKACCNB2CDK1CCNB1 | |
| SCHEMBL16942848 | 0.73 | PARP1 (0.49) | TAAR1PARP1HTR2AHTR2CRAD52 | |
| SCHEMBL21806815 | 0.73 | PDK2 (0.40) | PARP1AURKACCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-2308510-B1 | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8501793-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130143934-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-8404858-B2 | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080114043-A1 | Medicinal Composition for Inhalation | ONO PHARMACEUTICAL CO., LTD (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1886693-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20070167459-A1 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1806148-A1 | MEDICINAL COMPOSITION FOR INHALATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1707208-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1571146-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | PTGFR, PTGIS, PTGIR | TAAR1 2037/4885PARP1 4186/4885HTR2A 1886/4885 |
| US-20080114043-A1 | Medicinal Composition for Inhalation | PTGER2, PTGER1, PTGIS | TAAR1 1734/4885PARP1 2085/4885HTR2A 747/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885PARP1 85/4885HTR2A 3621/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TAAR1 2432/4885PARP1 101/4885HTR2A 3308/4885 |
| US-20130143934-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | PTGER3, PTGER2, PTGER1 | TAAR1 712/4885PARP1 2798/4885HTR2A 294/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | TAAR1 2149/4885PARP1 2549/4885HTR2A 2540/4885 |
| US-20070167459-A1 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | CXCR4, CXCL12, CXCR3 | TAAR1 1683/4885PARP1 1917/4885HTR2A 1761/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885PARP1 85/4885HTR2A 3621/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885PARP1 85/4885HTR2A 3621/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | TAAR1 2432/4885PARP1 101/4885HTR2A 3308/4885 |
| US-20090012077-A1 | Novel Compound - 827 | CTSS, CTSF, CTSB | TAAR1 4785/4885PARP1 3099/4885HTR2A 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.